Daniel Kasuga, MD
Retina Specialist · El Paso, TXNPI 1568786176
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,982 of the $9,272 with a category attached, or 75.3%. 21 manufacturers reported payments, led by Genentech USA, Inc. at 36.1% of the total. Reporting peaked in 2024 at $4,079 and has fallen 70.5% since, to $1,205 in 2025.
Across 83 payments — averaging $111.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$3K
- Regeneron$1K
- Alcon$984
- Regeneron Healthcare Solutions, Inc.$731
- Astellas Pharma US Inc$539
- Carl Zeiss Meditec USA, Inc.$308
- plus $2K from 15 others
What the payments were for
- Consulting fees$2,29025%
- Food & beverage$6,98275%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 14 | $3,352 |
| Regeneron | 11 | $1,082 |
| Alcon | 9 | $984 |
| Regeneron Healthcare Solutions, Inc. | 12 | $731 |
| Astellas Pharma US Inc | 6 | $539 |
| Carl Zeiss Meditec USA, Inc. | 3 | $308 |
| Alimera Sciences, Inc. | 3 | $299 |
| AbbVie | 4 | $273 |
| Coherus Oncology, Inc. | 2 | $229 |
| Eyepoint US, Inc. | 2 | $205 |
| Amgen | 2 | $196 |
| Biogen | 2 | $165 |
| Apellis Pharmaceuticals, Inc. | 2 | $148 |
| Sandoz | 2 | $143 |
| Bausch & Lomb Americas Inc. | 1 | $111 |
| Harrow Eye, LLC | 2 | $111 |
| Iridex Corporation | 2 | $106 |
| Novartis | 1 | $100 |
| Spark Therapeutics, Inc. | 1 | $99 |
| US Oncology Corporate, Inc. | 1 | $70 |
| Genentech, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,272 in reported general payments places this provider in the 75th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 204 | $7,027 |
| MoxifloxacinMoxifloxacin Hcl | 129 | $3,977 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,694 |
| Cyclopentolate Hcl | 49 | $785 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $525 |
| Brimonidine Tartrate | 51 | $243 |
| Latanoprost | 21 | $69 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in El Paso
- Dinesh BahlEl Paso$13K
- Jeremy CuthbertsonEl Paso$12K
- David MetrikinEl Paso$11K
- Gregory TrubowitschEl Paso$8K
- Richard HwangEl Paso$3K
- Erica Alvarez GonzalezEl Paso$2K
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.